AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

Article Details

Citation

Copy to clipboard

Waeber B, Burnier M

AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

Expert Rev Cardiovasc Ther. 2003 May;1(1):23-33.

PubMed ID

15030294 [ View in PubMed

]

Abstract

Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor). This compound lowers blood pressure dose-dependently in hypertensive patients and has a placebo-like tolerability. The antihypertensive efficacy of irbesartan is greatly enhanced by the coadministration of a diuretic, and fixed-dose combinations of irbesartan and hydrochlorothiazide are now available. Irbesartan-based treatment appears especially effective for high-risk patients, such as those with diabetes, renal disease and cardiac hypertrophy. In patients with Type 2 diabetes, irbesartan delays the development of nephropathy as well as the progression of renal failure. Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II. Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Irbesartan	Type-1 angiotensin II receptor	Protein	Humans	Yes	Antagonist	Details